Resolution Therapeutics Announces Positive Interim Phase I/II EMERALD Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease
- Six-month interim data showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation versus an external control
- RTX001 was well tolerated with no infusion-related serious adverse reactions; biomarker analyses demonstrated suppression of key inflammatory pathways and reduced fibrogenesis
- Positive interim results support advancement of RTX001 towards a planned U.S. pivotal trial, with a pre-IND meeting with the FDA scheduled for December 2026
London, UK, November 5, 2026: Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company pioneering engineered Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announced positive interim six-month data from its Phase I/II EMERALD trial evaluating RTX001, an investigational autologous engineered RMT, in patients with end-stage liver disease (ESLD).
